Scalper1 News
Biotechs and drugmaker stocks are leading today’s losses, and Regeneron Pharmaceuticals (REGN) is showing particular weakness. Despite announcing European Commission marketing approval for its cholesterol drug Praluent, the biotech’s shares are crumbling. The stock was down 8% in afternoon trade. Volume was heavy. The move is a substantial blow to shares, which are now trading below the 200-day line for the first time in more than a year. Scalper1 News
Scalper1 News